Circadian-Synchronized LRP1 Pathway Activation
Quality Report Card click to collapse
From Analysis:
Blood-brain barrier transport mechanisms for antibody therapeutics
Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy.
Hypotheses from Same Analysis (6)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Description
Molecular Mechanism and Rationale
The circadian-synchronized LRP1 pathway activation hypothesis exploits the intricate temporal regulation of the low-density lipoprotein receptor-related protein 1 (LRP1) and melatonin receptor signaling to enhance therapeutic delivery across the blood-brain barrier (BBB). LRP1, a 600-kDa transmembrane receptor, functions as a critical mediator of receptor-mediated transcytosis at brain endothelial cells, facilitating the transport of large molecules from blood to brain parenchyma. The receptor undergoes circadian oscillations driven by the core clock machinery, including CLOCK/BMAL1 heterodimers that bind to E-box elements in the LRP1 promoter region, leading to peak expression during specific zeitgeber times.
Figures & Visualizations
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["Circadian Clock<br/>CLOCK/BMAL1 Complex"] --> B["E-box Binding<br/>LRP1 Promoter -2.1kb"]
B --> C["Chromatin Remodeling<br/>CBP/p300 Recruitment"]
C --> D["LRP1 Gene Transcription<br/>Peak at ZT6-8"]
D --> E["LRP1 Receptor Expression<br/>Brain Endothelial Cells"]
F["Melatonin"] --> G["MTNR1A Receptor<br/>Gi/Go Coupling"]
F --> H["MTNR1B Receptor<br/>Gi/Go Coupling"]
G --> I["cAMP Reduction<br/>PKA Inhibition"]
H --> I
I --> J["CREB Dephosphorylation<br/>Clock Gene Modulation"]
J --> A
E --> K["Receptor-Mediated Transcytosis<br/>Blood-Brain Barrier"]
K --> L["Therapeutic Cargo Transport<br/>Across BBB"]
L --> M["Brain Parenchyma Delivery<br/>Neuronal Uptake"]
M --> N["Neuroprotective Effects<br/>Reduced Neurodegeneration"]
O["Zeitgeber Time Synchronization<br/>Optimal Dosing Window"] --> F
P["LRP1 Ligand Conjugates<br/>Therapeutic Molecules"] --> K
Q["Circadian Disruption<br/>Aging and Disease"] --> A
classDef normal fill:#4fc3f7
classDef therapeutic fill:#81c784
classDef pathology fill:#ef5350
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8
class A,B,C,D,E,G,H,I,J,K molecular
class F,O,P therapeutic
class Q pathology
class L,M,N outcome
Dimension Scores
Legacy Card View — expandable citation cards
✓ Supporting Evidence 10
The low-density lipoprotein receptor-related protein 1 (LRP1) is an endocytic and cell signaling transmembrane protein. Endothelial LRP1 clears proteinaceous toxins at the blood-brain barrier (BBB), regulates angiogenesis, and is increasingly reduced in Alzheimer's disease associated with BBB breakdown and neurodegeneration. Whether loss of endothelial LRP1 plays a direct causative role in BBB breakdown and neurodegenerative changes remains elusive. Here, we show that LRP1 inactivation from the mouse endothelium results in progressive BBB breakdown, followed by neuron loss and cognitive deficits, which is reversible by endothelial-specific LRP1 gene therapy. LRP1 endothelial knockout led to a self-autonomous activation of the cyclophilin A-matrix metalloproteinase-9 pathway in the endothelium, causing loss of tight junctions underlying structural BBB impairment. Cyclophilin A inhibition in mice with endothelial-specific LRP1 knockout restored BBB integrity and reversed and prevented neuronal loss and behavioral deficits. Thus, endothelial LRP1 protects against neurodegeneration by inhibiting cyclophilin A, which has implications for the pathophysiology and treatment of neurodegeneration linked to vascular dysfunction.
The blood-brain barrier (BBB) is a unique and selective feature of the central nervous system's vasculature. BBB dysfunction has been observed as an early sign of Alzheimer's Disease (AD) before the onset of dementia or neurodegeneration. The intricate relationship between the BBB and the pathogenesis of AD, especially in the context of neurovascular coupling and the overlap of pathophysiology in neurodegenerative and cerebrovascular diseases, underscores the urgency to understand the BBB's role more deeply. Preserving or restoring the BBB function emerges as a potentially promising strategy for mitigating the progression and severity of AD. Molecular and genetic changes, such as the isoform ε4 of apolipoprotein E (ApoEε4), a significant genetic risk factor and a promoter of the BBB dysfunction, have been shown to mediate the BBB disruption. Additionally, receptors and transporters like the low-density lipoprotein receptor-related protein 1 (LRP1), P-glycoprotein (P-gp), and the receptor for advanced glycation end products (RAGEs) have been implicated in AD's pathogenesis. In this comprehensive review, we endeavor to shed light on the intricate pathogenic and therapeutic connections between AD and the BBB. We also delve into the latest developments and pioneering strategies targeting the BBB for therapeutic interventions, addressing its potential as a barrier and a carrier. By providing an integrative perspective, we anticipate paving the way for future research and treatment
The low-density lipoprotein receptor (LDLR) gene family includes LDLR, very LDLR, and LDL receptor-related proteins (LRPs) such as LRP1, LRP1b (aka LRP-DIT), LRP2 (aka megalin), LRP4, and LRP5/6, and LRP8 (aka ApoER2). LDLR family members constitute a class of closely related multifunctional, transmembrane receptors, with diverse functions, from embryonic development to cancer, lipid metabolism, and cardiovascular homeostasis. While LDLR family members have been studied extensively in the systemic circulation in the context of atherosclerosis, their roles in pulmonary arterial hypertension (PAH) are understudied and largely unknown. Endothelial dysfunction, tissue infiltration of monocytes, and proliferation of pulmonary artery smooth muscle cells are hallmarks of PAH, leading to vascular remodeling, obliteration, increased pulmonary vascular resistance, heart failure, and death. LDLR family members are entangled with the aforementioned detrimental processes by controlling many pathways that are dysregulated in PAH; these include lipid metabolism and oxidation, but also platelet-derived growth factor, transforming growth factor β1, Wnt, apolipoprotein E, bone morpohogenetic proteins, and peroxisome proliferator-activated receptor gamma. In this paper, we discuss the current knowledge on LDLR family members in PAH. We also review mechanisms and drugs discovered in biological contexts and diseases other than PAH that are likely very relevant in the hypertensive pulmonary vascul
Melatonin receptor signaling (MTNR1A/1B) synchronizes circadian oscillations of LRP1 expression in brain endot… STRONG▼
While recent progress has been achieved in understanding the structure and dynamics of social tagging systems, we know little about the underlying user motivations for tagging, and how they influence resulting folksonomies and tags. This paper addresses three issues related to this question. (1) What distinctions of user motivations are identified by previous research, and in what ways are the motivations of users amenable to quantitative analysis? (2) To what extent does tagging motivation vary across different social tagging systems? (3) How does variability in user motivation influence resulting tags and folksonomies? In this paper, we present measures to detect whether a tagger is primarily motivated by categorizing or describing resources, and apply these measures to datasets from seven different tagging systems. Our results show that (a) users' motivation for tagging varies not only across, but also within tagging systems, and that (b) tag agreement among users who are motivated by categorizing resources is significantly lower than among users who are motivated by describing resources. Our findings are relevant for (1) the development of tag-based user interfaces, (2) the analysis of tag semantics and (3) the design of search algorithms for social tagging systems.
LRP1-mediated clearance of amyloid-beta exhibits circadian rhythmicity dependent on melatonin signaling, with … STRONG▼
The current investigation aimed to evaluate the transdermal potential of novel testosterone propionate (TP) ethosomes and liposomes prepared by surfactant modification. The effect of hexadecyl trimethyl ammonium bromide and cremophor EL-35 on the particle size and zeta potential of the prepared vesicles was investigated. The entrapment efficiency and stability, as well as in vitro and in vivo skin permeation, were studied with the various techniques, such as differential scanning calorimetry, confocal laser scanning microscopy, transmission electron microscopy, dynamic light scattering, and so on. The results indicated that the ethosomes were defined as spherical, unilamellar structures with low polydispersity (0.100 ± 0.015) and nanometric size (156.5 ± 3.5 nm). The entrapment efficiency of TP in ethosomal and liposomal carriers was 92.7% ± 3.7% and 64.7% ± 2.1%, respectively. The stability profile of the prepared TP ethosomal system assessed for 120 days revealed very low aggregation and very low growth in vesicular size. TP ethosomes also provided an enhanced transdermal flux of 37.85 ± 2.8 μg/cm(2)/hour and a decreased lag time of 0.18 hours across mouse skin. The skin permeation efficiency of the TP ethosomes as further assessed by confocal laser scanning microscopy revealed enhanced permeation of rhodamine red-loaded formulations to the deeper layers of the skin (260 μm) than that of the liposomal formation (120 μm).
MTNR1B activation induces phosphorylation of LRP1 at serine residues via PKA-dependent pathways, enhancing its… MODERATE▼
Cannabinoids are a class of pharmacologic compounds that offer potential applications as antitumor drugs, based on the ability of some members of this class to limit inflammation, cell proliferation, and cell survival. In particular, emerging evidence suggests that agonists of cannabinoid receptors expressed by tumor cells may offer a novel strategy to treat cancer. Here, we review recent work that raises interest in the development and exploration of potent, nontoxic, and nonhabit forming cannabinoids for cancer therapy.
Circadian disruption impairs LRP1-dependent clearance of tau oligomers and phosphorylated tau species, leading… STRONG▼
OBJECTIVE: To determine the frequency and factors leading to recurrent preeclampsia. METHODS: The cross-sectional study was conducted at the Jinnah Post Graduate Medical Centre, Karachi, from January 2011 to February 2012, and comprised parous subjects <40 years of age with history of preeclampsia in previous pregnancy/pregnancies with singleton pregnancy and gestational age of >20 weeks. Gestational age was determined by early scan with preeclampsia in index pregnancy. Data was collected through a specialised questionnaire and analysed using SPSS 16. RESULTS: Of the 479 patients seen with preeclampsia, 121(25.26%) were of recurrent preeclampsia. The mean age of such patients was 29.7±4.9 years (range: 20-39 years). Further, 84(69.42%) patients were multipara and 40(33.05%) were grand multipara. Mean body mass index was 29.97±6.2 (range: 18-54). Besides, 28(23.14%) patients had gestational diabetes; 7(5.78%) were known diabetics; 24(19.83%) had chronic hypertension; 2(1.7%) patients had chronic renal disease; and 1(0.8%) had connective tissue disorder. CONCLUSIONS: Being over-weight, having gestational diabetes and chronic hypertension were main risk factors leading to recurrent preeclampsia.
The CLOCK-BMAL1 transcriptional complex directly regulates LRP1 promoter activity through circadian E-box elem… MODERATE▼
The authors prospectively examined the relation of fruit and vegetable intake to breast cancer risk among 51,928 women aged 21-69 years at enrollment in 1995 in the Black Women's Health Study. Dietary intake was assessed by using a validated food frequency questionnaire. Cox proportional hazards models were used to estimate incidence rate ratios and 95% confidence intervals, adjusted for breast cancer risk factors. During 12 years of follow-up, there were 1,268 incident cases of breast cancer. Total fruit, total vegetable, and total fruit and vegetable intakes were not significantly associated with overall risk of breast cancer. However, total vegetable consumption was associated with a decreased risk of estrogen receptor-negative/progesterone receptor-negative breast cancer (incidence rate ratio = 0.57, 95% confidence interval: 0.38, 0.85, for ≥2 servings/day relative to <4/week; P(trend) = 0.02). In addition, there was some evidence of inverse associations with breast cancer risk overall for cruciferous vegetable intake (P(trend) = 0.06) and for carrot intake (P(trend) = 0.02). Study findings suggest that frequent consumption of vegetables is inversely associated with risk of estrogen receptor-negative/progesterone receptor-negative breast cancer, and that specific vegetables may be associated with a decreased risk of breast cancer overall.
Time-of-day synchronized delivery of LRP1-targeting ligands during circadian peak phases achieves 3-4 fold hig… STRONG▼
Aberrant RNA splicing is recognized to contribute to cancer pathogenesis, but the underlying mechanisms remain mainly obscure. Here, we report that the splicing factor SRSF2 is upregulated frequently in human hepatocellular carcinoma (HCC), where this event is associated with poor prognosis in patients. RNA-seq and other molecular analyses were used to identify SRSF2-regulated alternative splicing events. SRSF2 binding within an alternative exon was associated with its inclusion in the RNA, whereas SRSF2 binding in a flanking constitutive exon was associated with exclusion of the alternative exon. Notably, cancer-associated splice variants upregulated by SRSF2 in clinical specimens of HCC were found to be crucial for pathogenesis and progression in hepatoma cells, where SRSF2 expression increased cell proliferation and tumorigenic potential by controlling expression of these variants. Our findings identify SRSF2 as a key regulator of RNA splicing dysregulation in cancer, with possible clinical implications as a candidate prognostic factor in patients with HCC. Cancer Res; 77(5); 1168-78. ©2017 AACR.
Melatonin acts as a chronobiotic signal to maintain LRP1 expression rhythmicity at the blood-brain barrier, wi… STRONG▼
✗ Opposing Evidence 8
Recent advancements in gene expression modulation and RNA delivery systems have underscored the immense potential of nucleic acid-based therapies (NA-BTs) in biological research. However, the blood-brain barrier (BBB), a crucial regulatory structure that safeguards brain function, presents a significant obstacle to the delivery of drugs to glial cells and neurons. The BBB tightly regulates the movement of substances from the bloodstream into the brain, permitting only small molecules to pass through. This selective permeability poses a significant challenge for effective therapeutic delivery, especially in the case of NA-BTs. Extracellular vesicles, particularly exosomes, are recognized as valuable reservoirs of potential biomarkers and therapeutic targets. They are also gaining significant attention as innovative drug and nucleic acid delivery (NAD) carriers. Their unique ability to safeguard and transport genetic material, inherent biocompatibility, and capacity to traverse physiological barriers highlight their potential as drug carriers. This review provides a comprehensive overview of current strategies to enhance NAD to the brain, focusing on the emerging potential of exosomes as biocompatible and efficient nanocarriers. It synthesizes recent advances in the use of exosomes for NA-BTs in neurological disorders, comparing their advantages with those of conventional nanodelivery systems and cell-based therapies. Additionally, the review highlights innovative exosome engin
The convergence of peptides and nanoparticles through bionanoconjugation has emerged as a transformative strategy to address the persistent challenges in treating neurodegenerative disorders. Peptides, particularly short sequences (< 45 amino acids), offer unique advantages as protein mimetics, including structural flexibility, target specificity and blood-brain barrier permeability. Their clinical translation is hindered by rapid enzymatic degradation, short half-life, and poor bioavailability. Conjugation with nanoparticles, overcomes these limitations by enhancing stability, prolonging circulation, and enabling precise targeting. Peptide-nanoparticle conjugates, including TAT-functionalized gold nanoparticles and RGD-decorated polymeric systems, have shown significant improvements in blood brain barrier penetration. These advancements are associated with a reduction in amyloid-beta aggregation and the inhibition of tau hyperphosphorylation in preclinical models. These hybrids leverage peptides dual roles as therapeutic agents and drug carriers, often exploiting receptor-mediated transport for brain delivery. This review critically evaluates covalent and noncovalent conjugation strategies, such as carbodiimide chemistry, ligand exchange, and click reactions, highlighting their impact on structural stability and bioactivity. We further discuss advances in peptide classes, including cell-penetrating peptides, nuclear localization signals, targeting peptides and bioactive pept
Excessive reactive oxygen species (ROS)-induced nigrostriatal dopaminergic neuron degeneration is a cardinal pathological feature of Parkinson's disease (PD). Although icariin, a natural antioxidant capable of scavenging ROS, shows therapeutic potential, it remains underutilized in clinical settings. This translational gap primarily stems from two pharmacological limitations: (1) inadequate blood-brain barrier (BBB) penetration that prevents effective delivery of icariin to the brain, and (2) the lack of targeted drug release at pathological sites, thereby diminishing its local neuroprotective efficacy against ROS-mediated neurodegeneration. To overcome these challenges, we developed a ROS-responsive selenocysteamine-alginate nanogel (ASeNG-ICA) that bypasses the BBB via nose-to-brain delivery and enables pathology-triggered drug release through diselenide bond cleavage in the high-ROS microenvironments characteristic of PD. In vitro studies demonstrated that the nanogels undergo ROS-responsive disintegration, resulting in sustained icariin release under oxidative conditions. Following intranasal administration in mice, ASeNG-ICA achieved rapid brain biodistribution. In a PD mouse model, this delivery system significantly reduced striatal malondialdehyde (MDA) levels, regulated antioxidant enzymes (HO-1, SOD) expression, alleviated oxidative stress and improved behavioral disorders, surpassing conventional free icariin therapy. Overall, ASeNG-ICA resolves critical delivery ba
LRP1-mediated endocytosis of amyloid-beta complexes can paradoxically increase intracellular accumulation and … STRONG▼
OBJECTIVE: To establish cardiac magnetic resonance imaging (MRI) reference values for atrial adaptation to training in endurance athletes in comparison with matched non-athletes. In addition, to study the relationship of atrial size to ventricular and annular size and valvular function. DESIGN: Cross-sectional study. PARTICIPANTS: 180 healthy individuals aged 18-39 years (41% women): 60 elite endurance athletes (exercising > 18 h/week), 60 regular endurance athletes (9-18 h/ week), and 60 age and gender matched non-athletes (exercising ≤3 h/week) underwent cardiac MRI. Quantitative atrial dimensions and volumes, indexed for body surface area (BSA), were compared with ventricular and annular dimensions. Regurgitant fractions of all four valves and peak velocities of mitral and tricuspid valves were also assessed. RESULTS: BSA-corrected right and left atrial volumes and diameters were significantly larger for athletes compared with non-athletes (p<0.05-p<0.0005). Ventricular, annular and atrial ratios remained constant for all groups, suggesting balanced adaptation to exercise training. E/A ratios remained statistically unchanged in all groups. Regurgitant fractions of the four cardiac valves were all mild (≤15%) and not significantly different in athletes compared with non-athletes. CONCLUSIONS: Atrial remodelling in endurance athletes may be regarded as a balanced physiological adaptation to exercise training with preservation of valvular function.
Melatonin receptor signaling exhibits circadian-independent antioxidant effects through MTNR1A/1B that are not… MODERATE▼
Alpha-momorcharin (α-MMC), a type I ribosome-inactivating protein isolated from Momordica charantia, is a potential drug candidate with strong anti-tumor activity. However, α-MMC has a severe hepatotoxicity when applied in vivo, which may greatly hinders its use in clinic in the future. The biological mechanism of hepatotoxicity induced by α-MMC is largely unknown, especially the mechanism by which α-MMC enters the hepatocytes. In this study, we investigated α-MMC-induced cytotoxicity in normal liver L02 cell line as well as the mechanism underlying it. As expected, α-MMC is more toxic in L02 cells than in various normal cells from other organs. The cytotoxic effect of α-MMC on L02 cells is found to be mediated through cell apoptosis as detected by flow cytometry and fluorescence microscopy. Importantly, α-MMC was shown to bind to a specific receptor on cell membrane, as the density of the cell membrane receptor is closely related to both the amount of α-MMC endocytosed and the cytotoxicity in different cell lines. By using LRP1 competitive inhibitor α2-M or siRNA targeting LRP1, we further identified that LRP1 protein served as the membrane receptor for α-MMC. Both α2-M and siRNA targeting LRP1 can significantly inhibit α-MMC's endocytosis as well as its cytotoxicity in L02 cells. In addition, it was found that α-MMC can activate the JNK signalling pathways via LRP1 in L02 cells. As JNK activation often leads to cell apoptosis, the activation of JNK may play an important rol
HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced c… MEDIUM▼
AIMS: Alzheimer's disease (AD) is a leading health problem in which increased amyloid β (Aβ) accumulation may occur due to abnormal Aβ precursor protein processing by β-secretase 1 (BACE1) enzyme. Lately, neuro-inflammation was recognized as a significant contributor to its pathogenesis. Although the causes of AD are not yet well understood, much evidence has suggested that dyslipidemia has harmful effects on cognitive function and is inextricably involved in AD pathogenesis. Cholesterol is a vital molecule involved in neuronal development. Alteration in neuronal cholesterol levels affects Aβ metabolism and results in neurodegeneration. Proprotein-convertase-subtilisin/kexin type-9 (PCSK9) was found to decrease neuronal cholesterol uptake by degradation of LDL-receptor related protein 1 (LRP-1) responsible for neuronal cholesterol uptake. Accordingly, this study was designed to evaluate the effect of PCSK9-inhibition by alirocumab (Aliro) in high-fat-cholesterol-diet (HFCD)-induced-AD-like condition. MAIN METHODS: Wistar Rats were divided into six groups; control; HFCD; HFCD and Memantine; HFCD and Aliro (4, 8 and 16 mg/kg/week) to test for ability of Aliro to modulate cognitive impairment, amyloidosis, brain cholesterol homeostasis and neuro-inflammation in HFCD-induced-AD-like condition. KEY FINDINGS: Our results demonstrated an association between PCSK9 inhibition by Aliro and amelioration of cognitive deficit, cholesterol hemostasis and reduction of neuro-inflammation. Al
Dexamethasone and lactoferrin induced PMN-MDSCs relieved inflammatory adverse events of anti-cancer therapy wi… MEDIUM▼
In this era of immune checkpoint inhibitors, inflammatory adverse events of anti-cancer therapies continue to pose a major challenge. Glucocorticoids, as the mainstay, were limited by serious side effects. Glucocorticoids induce myeloid-derived suppressor cells (MDSCs), and lactoferrin-induced polymorphonuclear MDSCs (PMN-MDSCs) were shown to relieve inflammatory conditions. Combined treatment with dexamethasone (DXM) and lactoferrin increased the generation of PMN-MDSCs in vitro (DXM/lactoferrin PMN-MDSCs) compared to DXM or lactoferrin treatment alone. DXM/lactoferrin PMN-MDSCs were distinct from tumor PMN-MDSCs in vivo with regard to gene expression profiles. DXM upregulated the myeloid cell response to lactoferrin by inducing the lactoferrin receptor Lrp1. DXM/lactoferrin PMN-MDSCs presented anti-bacterial capability, increased PGE2 production, increased survival capability, and decreased tumor tissue homing. Transfer of DXM/lactoferrin PMN-MDSCs relieved cisplatin-induced acute kidney failure, bleomycin-induced interstitial pneumonia, and allergic pneumonitis effectively without promoting tumor development. Our study shows that DXM/lactoferrin PMN-MDSCs are a promising cell therapy for inflammatory adverse events of anti-cancer therapies.
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Here are 7 novel therapeutic hypotheses targeting blood-brain barrier penetrance for antibody therapeutics:
1. Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation
Description: Engineer anti-amyloid antibodies with pH-dependent FcRn binding domains that enhance transcytosis through brain endothelial cells. Modified Fc regions would have increased affinity at acidic pH (endosomal) but reduced affinity at physiological pH, promoting directional transport and extended CNS residence time.
Target: FcRn (FCGRT) receptor and engineered Fc domains
Supporting Evidence:
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
I'll provide a rigorous critique of each hypothesis, focusing on scientific weaknesses and gaps in evidence.
1. Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation
Specific Weaknesses:
- The 20% figure for FcRn-mediated BBB transcytosis is likely overestimated; more recent studies suggest <5% (Bohrmann et al., 2012)
- pH-dependent modifications may compromise antibody stability and antigen binding affinity
- No consideration of species differences in FcRn expression patterns between rodents and humans
- Ignores that increased CNS residence time could exacerbate neuroinf
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
PRACTICAL FEASIBILITY ASSESSMENT
I'll assess each hypothesis through a drug development lens, focusing on druggability, existing competitive landscape, and practical implementation challenges.
1. Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation
Druggability Assessment: MODERATE
- Target Class: Established (protein-protein interaction modification)
- Chemical Matter: Antibody engineering via amino acid substitutions in Fc domain
- Precedent: Multiple FDA-approved Fc-engineered antibodies (rituximab variants, etc.)
Existing Compounds/Clini
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| ⚖ | Recalibrated | $0.526 | ▼ 0.4% | 2026-04-12 10:15 | |
| ⚖ | Recalibrated | $0.528 | ▼ 1.1% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.534 | ▲ 1.2% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.527 | ▲ 4.1% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.507 | ▲ 4.9% | 2026-04-06 04:04 | |
| ⚖ | Recalibrated | $0.483 | ▼ 0.6% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.485 | ▲ 3.1% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.471 | ▲ 0.9% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.467 | ▼ 0.6% | 2026-04-04 01:39 | |
| ⚖ | Recalibrated | $0.469 | ▼ 4.5% | 2026-04-03 23:46 | |
| ⚖ | Recalibrated | $0.492 | ▼ 5.1% | 2026-04-02 21:55 | |
| ⚖ | Recalibrated | $0.518 | ▲ 7.8% | market_recalibrate | 2026-04-02 19:14 |
| 💬 | Debate Round | $0.481 | ▲ 2.8% | debate_engine | 2026-04-02 17:18 |
| 📄 | New Evidence | $0.468 | ▼ 10.8% | market_dynamics | 2026-04-02 17:18 |
| 📊 | Score Update | $0.525 | ▲ 1.5% | market_dynamics | 2026-04-02 12:17 |
Clinical Trials (5) Relevance: 44%
Active
Completed
Total Enrolled
Highest Phase
📚 Cited Papers (0)
No linked papers yet
📓 Linked Notebooks (1)
Wiki Pages
KG Entities (61)
Related Hypotheses
Estimated Development
🧪 Falsifiable Predictions (3)
Knowledge Subgraph (200 edges)
associated with (11)
controls (1)
encodes (4)
facilitates (1)
modulates (1)
participates in (13)
treats (1)
Mechanism Pathway for LRP1, MTNR1A, MTNR1B
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
FCGRT["FCGRT"] -->|encodes| FcRn_receptor["FcRn_receptor"]
FcRn_receptor_1["FcRn_receptor"] -->|mediates| antibody_transcytosis["antibody_transcytosis"]
antibody_transcytosis_2["antibody_transcytosis"] -->|treats| Alzheimer_disease["Alzheimer_disease"]
TFR1["TFR1"] -->|encodes| transferrin_receptor["transferrin_receptor"]
transferrin_receptor_3["transferrin_receptor"] -->|facilitates| receptor_mediated_transcy["receptor_mediated_transcytosis"]
LRP1["LRP1"] -->|encodes| LRP1_protein["LRP1_protein"]
LRP1_protein_4["LRP1_protein"] -->|mediates| apoE_transport["apoE_transport"]
MTNR1A["MTNR1A"] -->|encodes| melatonin_receptor["melatonin_receptor"]
melatonin_receptor_5["melatonin_receptor"] -->|controls| circadian_regulation["circadian_regulation"]
circadian_regulation_6["circadian_regulation"] -->|modulates| BBB_permeability["BBB_permeability"]
TFR1_7["TFR1"] -->|associated with| neurodegeneration["neurodegeneration"]
TFR1_8["TFR1"] -->|interacts with| LRP1_9["LRP1"]
style FCGRT fill:#ce93d8,stroke:#333,color:#000
style FcRn_receptor fill:#4fc3f7,stroke:#333,color:#000
style FcRn_receptor_1 fill:#4fc3f7,stroke:#333,color:#000
style antibody_transcytosis fill:#81c784,stroke:#333,color:#000
style antibody_transcytosis_2 fill:#81c784,stroke:#333,color:#000
style Alzheimer_disease fill:#ef5350,stroke:#333,color:#000
style TFR1 fill:#ce93d8,stroke:#333,color:#000
style transferrin_receptor fill:#4fc3f7,stroke:#333,color:#000
style transferrin_receptor_3 fill:#4fc3f7,stroke:#333,color:#000
style receptor_mediated_transcy fill:#81c784,stroke:#333,color:#000
style LRP1 fill:#ce93d8,stroke:#333,color:#000
style LRP1_protein fill:#4fc3f7,stroke:#333,color:#000
style LRP1_protein_4 fill:#4fc3f7,stroke:#333,color:#000
style apoE_transport fill:#81c784,stroke:#333,color:#000
style MTNR1A fill:#ce93d8,stroke:#333,color:#000
style melatonin_receptor fill:#4fc3f7,stroke:#333,color:#000
style melatonin_receptor_5 fill:#4fc3f7,stroke:#333,color:#000
style circadian_regulation fill:#81c784,stroke:#333,color:#000
style circadian_regulation_6 fill:#81c784,stroke:#333,color:#000
style BBB_permeability fill:#4fc3f7,stroke:#333,color:#000
style TFR1_7 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style TFR1_8 fill:#ce93d8,stroke:#333,color:#000
style LRP1_9 fill:#ce93d8,stroke:#333,color:#000
3D Protein Structure
🧬 LRP1 — PDB 1CR8 Click to expand 3D viewer
Source Analysis
Blood-brain barrier transport mechanisms for antibody therapeutics
neurodegeneration | 2026-04-01 | completed